Abstract: Anti-LAG3 mAb is a monoclonal antibody targets lymphocyte activating 3 (LAG3) that involves in T cell immune regulation. Anti-LAG3 mAb as an antagonistic antibody removes LAG3 mediated T cell inhibition to make nonspecific immune activation, for the treatment of various solid tumors and hematologic cancers.Summary: Anti-LAG3 mAb differs from the leading competitor (monoclonal antibody 25F7 from Bristol Myers Squibb) with different epitope and higher affinity. Its optimal safety and efficacy can ensure its market share.References: https://www.protheragen.com/available-projects/a-novel-anti-lag3-monoclonal-antibody/
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Wat is de impact van bewegen op de werkvloer bij verschillende beroepen?
Jhon van Heel
SARS-CoV-2 Introduction_Creative Biolabs
Complement Therapeutics_Creative Biolabs
CAR Design & Construction Service_Creative Biolabs
Active lifestyle and cognitive performance in older adults
Hana Georgi, Zuzana Frydrychová